Compare Merck & Co., Inc. (MRK) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Carparts.Com Inc — how do they compare? Merck & Co., Inc. trades at $130.29 (market cap $323.00B), while Carparts.Com Inc trades at $6.41 (market cap $52.07M). The key difference: Merck & Co., Inc. is far larger — about 6203.2× Carparts.Com Inc's market cap, and Merck & Co., Inc. pays a 2.6% dividend while Carparts.Com Inc pays none. Which is the better fit depends on your goals.
| MRK | PRTS | |
|---|---|---|
Market Cap | $323.00B | $52.07M |
Sector | Health | Consumer Cyclical |
52-Week High | $131.84 | $11.40 |
52-Week Low | $77.60 | $3.88 |
Enterprise Value | $369.77B | $67.05M |
Dividend Yield | 2.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.
CarParts.com (PRTS) is trading at $6.75, up 16.68% with bullish technical signals and strong analyst support. The company shows improving operational performance with three consecutive quarterly earnings beats, though it remains unprofitable with negative net margins. Recent developments include a 10:1 reverse stock split completed in May 2026 and a new $25 million credit facility, providing financial flexibility amid challenging market conditions.
The outlook remains cautiously optimistic with 60% analyst buy ratings supporting recovery potential, but significant risks persist from sustained losses, negative cash flow, and competitive pressures. Investors should focus on the company's ability to leverage proprietary data advantages while monitoring progress toward profitability in the competitive auto parts e-commerce sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
